Achillion Pharmaceuticals (NASDAQ:ACHN) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

A number of other research analysts have also commented on ACHN. Chardan Capital restated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Monday, November 6th. Finally, Leerink Swann restated a “buy” rating and issued a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $5.13.

Shares of Achillion Pharmaceuticals (NASDAQ ACHN) remained flat at $$2.99 during mid-day trading on Friday. The company had a trading volume of 1,467,546 shares, compared to its average volume of 2,950,000. Achillion Pharmaceuticals has a fifty-two week low of $2.69 and a fifty-two week high of $5.66. The company has a market capitalization of $410.82, a price-to-earnings ratio of -6.10 and a beta of 1.52.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. During the same period last year, the business earned ($0.15) earnings per share. research analysts predict that Achillion Pharmaceuticals will post -0.63 EPS for the current year.

In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.24% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Senzar Asset Management LLC acquired a new position in Achillion Pharmaceuticals during the second quarter worth $4,966,000. Candriam Luxembourg S.C.A. acquired a new position in Achillion Pharmaceuticals during the third quarter worth $1,976,000. Dimensional Fund Advisors LP raised its stake in Achillion Pharmaceuticals by 204.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,868,968 shares of the biopharmaceutical company’s stock worth $8,579,000 after acquiring an additional 1,255,962 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Achillion Pharmaceuticals by 11.4% during the second quarter. Bank of New York Mellon Corp now owns 611,634 shares of the biopharmaceutical company’s stock worth $2,808,000 after acquiring an additional 62,515 shares in the last quarter. Finally, Sarissa Capital Management LP acquired a new position in Achillion Pharmaceuticals during the third quarter worth $9,594,000. Hedge funds and other institutional investors own 76.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Achillion Pharmaceuticals (ACHN) Stock Rating Lowered by BidaskClub” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/13/achillion-pharmaceuticals-achn-stock-rating-lowered-by-bidaskclub.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.